Spotted Lanternfly Egg Hunt Activity for Kids

Spotted Lanternfly Egg Masse

Spotted Lanternfly typically lay their egg masses on the undersides of tree branches.

Giroud Tree and Lawn Logo

Giroud Tree and Lawn shares how kids (and adults!) can look for Spotted Lanternfly Eggs, and what to do with them.

HUNTINGDON VALLEY, PA, UNITED STATES, March 31, 2021 / — Spotted Lanternfly are beautiful but destructive insects that have invaded Pennsylvania. These insects are doing a lot of damage, but the good news is kids can help. Just in time for Easter, kids can hunt for eggs- – – Spotted Lanternfly Eggs!

What Is Spotted Lanternfly?
Spotted Lanternfly is a dangerous, invasive pest. Invasive means this insect is from another country and it has invaded the United States. Spotted Lanternfly came from Asia to our country a few years ago. They’ve been multiplying and spreading all over the country.

Why Is Spotted Lanternfly Bad?
Spotted Lanternfly are a problem in many ways because they:
• destroy grapes, apples, and other important crops that are grown by farmers in America.
• damage trees when they feed from them.
• make a sticky mess when they are eating, dripping something called “honeydew” down on to anything underneath them.
• attract stinging bees who love to eat the honeydew they drip.

What do Spotted Lanternfly Look Like?
The Spotted Lanternfly go through 4 different life cycles.
1. Nymphs, black with white dots – the insects hatch from their eggs in May.
2. Nymphs, red with white dots and black marks, a little larger than the black nymphs.
3. Adults – In July, the insects get wings! The underside of their wings looks a lot more colorful than the top, so it’s important to know what the wings look like on both sides.
4. Egg Masses – Starting in late September, the females will lay their eggs and cover them with a protective substance that hardens to look like clay. These egg masses will stay there all winter long until the next generation of nymphs hatches the following May.

How Kids Can Help Stop the Spread of Spotted Lanternfly
Spotted Lanternfly can lay their eggs anywhere, even underneath a slide!
Now is the perfect time to go on Spotted Lanternfly Egg Hunt! Kids can check all the trees in the front and backyard. Egg masses are grayish brown and look like dried bubble gum. If kids find any, scrape them off with a stick or a card and destroy them by dropping them in a baggy with hand sanitizer or rubbing alcohol.

After checking all the trees, it’s time to look for Spotted Egg Masses in other places. The adult females lay eggs pretty much anywhere! They usually lay them in places where the eggs will be out of sight from hungry predator bugs. Look on the underside of outdoor tables and chairs, railings, playhouses, swing sets, and slides.

To learn more about Spotted Lanternfly, visit Penn State’s Department of Agriculture Page.

For more information, visit Giroud's Spotted Lanternfly Info Page.

About Giroud Tree and Lawn
Giroud Tree and Lawn specializes in tree service, lawn care, and mosquito and tick control programs that make customers love doing business with the company since 1974. Serving Bucks, Montgomery, and Philadelphia Counties, the company offers professional tree and lawn evaluation, tree pruning, tree removal, insect and disease control, fertilizing, stump removal, traditional and 100% organic lawn programs, and mosquito and tick control. Giroud Arborists are certified by the International Society of Arboriculture (ISA) and have the knowledge and experience required to properly diagnose, treat and maintain trees and lawn health. The company is Accredited by the Tree Care Industry Association and Better Business Bureau. The “Giroud Treework for Charity” program donates free tree care services to parks, historical sites, and other non-profit organizations located in the Company’s service area. For more information, visit the company website at or call 215-682-7704.

Jeanne Hafner
Giroud Tree & Lawn
+1 2156827704
email us here
Visit us on social media:

Source: EIN Presswire

Delpor Appoints Jay Smith as Chief Commercial Officer to Lead Commercialization of Once-Yearly Risperidone Implant

Jay Smith, Delpor’s New CCO

Delpor’s Implant Technology

Smith will also be responsible for optimizing customer experience for Delpor’s implant products, as he oversaw over 23k procedures for another implant biotech

BRISBANE, CA, UNITED STATES, March 31, 2021 / — BRISBANE, CA, March 31, 2021 — Delpor, Inc. (Delpor), a clinical stage biopharmaceutical company that utilizes innovative technologies in order to develop once-yearly therapies for chronic conditions, announced the appointment of Jay Smith to the newly-created position of Chief Commercial Officer, where he will lead Delpor’s commercialization efforts, leveraging more than 25 years of global biopharmaceutical leadership and experience.

“I am excited to welcome Jay to Delpor as our new Chief Commercial Officer,” said Tassos Nicolaou, Delpor’s President and Chief Executive Officer. “Jay’s commercial track-record for results and his expertise and experience in the implant market make him the ideal person to lead Delpor’s commercial efforts.”

Mr. Smith most recently served as Chief Experience Officer at Intarcia Therapeutics. He was responsible for the commercial strategy to optimize the customer experience and drive Intarcia’s innovative implant technology platform. While at Intarcia, he led multiple usability studies and oversaw the clinical team responsible for over 23,000 implant insertion and removal procedures in over 30 countries as he optimized the customer experience for both clinicians and patients. Before joining Intarcia in 2013, Jay held senior executive commercial positions at J&J, Novartis, and Sunovion, launching several global blockbuster brands. Jay is known for his customer centric approach and is considered a thought leader in the implant space.

“I’m thrilled to be joining Delpor at such an exciting time for the company and looking forward to working with the entire team to bring Delpor’s innovative once-yearly therapies to patients, improving outcomes and addressing the unmet need of adherence in chronic disease,’ said Jay Smith, Chief Commercial Officer, Delpor.

Delpor’s PROZOR technology enables the sustained release of drugs from a non-mechanical, matchstick-long, implantable drug delivery device based on a unique formulation. The device is implanted in the abdomen during a simple, 10-minute in-office procedure, and delivers therapeutic levels of the drug for as long as one year. The company is focusing on CNS drugs. Delpor’s lead program (DLP-114) is a once-yearly formulation of the antipsychotic risperidone for schizophrenia maintenance therapy. Potential benefits include reduced relapses due to complete medication adherence for as long as one year after a single administration, and steady drug release without any adverse event inducing peaks, or sub-therapeutic troughs. The device may be easily removed within minutes if medically required.

About Delpor
Delpor is a clinical stage biopharmaceutical company that utilizes innovative technologies to develop once-yearly therapies for chronic conditions. The Company’s lead product is a 6-12-month formulation of Risperidone for the treatment of schizophrenia. Delpor is also pursuing 6-12-month formulations of other drugs targeting CNS conditions including Schizophrenia, Addiction, Spasticity, Parkinson’s, Alzheimer’s, and other conditions. Additional information can be found at
Forward-Looking Statements
To the extent any statements made in this release contain information that is not historical, these statements are essentially forward-looking and are subject to risks and uncertainties, including the difficulty of predicting FDA approvals, acceptance and demand for new pharmaceutical products, the impact of competitive products and pricing, new product development and launch, reliance on key strategic alliances, availability of raw materials, availability of additional intellectual property rights, availability of future financing sources, the regulatory environment and other risks the Company may identify from time to time in the future.

Tassos Nicolaou
Delpor, Inc
+1 415-480-6870
Visit us on social media:

Source: EIN Presswire

Acupuncture Anatomy and Myofascial Lines

Acupuncture meridians have an anatomical basis in myofascial lines. Research in acupuncture reveals that fasciae are stretched with needling. Master Tung's points are often located in regions with dense connective tissues and fascia.

Acupuncture Anatomy & Fasciae

Research on connective tissues demonstrate a possible anatomical basis for the acupuncture meridians.

UNITED STATES, March 31, 2021 / — There are many mysteries about acupuncture but research has shown it to be effective for a variety of disorders. While researchers have primarily focused on the nervous system for understanding acupuncture, the myofascial system provides many clues about acupunctures benefits. By mapping myofascial lines according to anatomical structures and functional muscle groups, it reveals much about the actions of acupuncture. Research by Dr. Helene Langevin has also found that acupuncture has the ability to stretch the fasciae, and this can account for how points in the hand can benefit distant regions of the body. The rest of this article will discuss how myofascial lines provide a basis for acupuncture anatomy, as well as how this relates to Master Tung's acupuncture points.

Research by Tom Myers has found that the fascia surrounding muscles form functional and structural units corresponding with anatomical planes. For instance, many of the muscles on the back of the body are interlinked through fasciae. Similarly, muscles on the anterior and lateral portions of the body are also interconnected through myofascial lines. On the posterior plane, the gastrocnemius muscle connects to the hamstrings, erector spinae, neck muscles and occipital fasciae. This posterior plane can be stretched as one unit in a simple forward bending position and is similar to the urinary bladder meridian. On the anterior plane, the SCM muscle connects to fasciae in the chest, abdomen, quadriceps and tibialias anterior muscles. This myofascial line is similar to the stomach meridian and can be stretched in backbends.

In Traditional Chinese Medicine (TCM) points on the stomach meridian and anterior portion of the leg are often used for lung and digestive conditions. While it is difficult to understand how points on the leg can treat the respiratory and digestive systems from a neurological perspective, the myofascial line theory provides a mechanical and anatomical basis for the actions of these points. Points like ST 36 and ST 40 therefore have a direct myofascial connection to respiratory muscles and fasciae in and around the chest. In a Taiwanese style of acupuncture known as Master Tung’s acupuncture, there are a group of three points on the thigh which are regarded as some of the most beneficial for lung disorders. These points are also located on the anterior fascial line, and have direct connections to the respiratory system.

On the posterior fascial line there are a group of acupuncture points in the achilles tendon that are used for treating neck and occipital disorders. Mapping the myofascial groups on this line reveals a direct connection from the achilles tendon to many of the small muscles in the neck. To help us understand how non-local points can effect distant regions of the body, we can draw from the principles of tensegrity. Tensegrity consists of two words, tension and integrity, and explains how tension moves through a system of compressed parts. When there is tension in the deep neck muscles, that tension can get transferred down the posterior line through the paraspinals, sacral fascia, hamstrings and calves. As the calve muscles converge to form the achilles tendons, needling into the achilles tendon can alleviate tension that has been distributed through the posterior line.

When we compare traditional acupuncture points with Master Tung’s points, and draw from the principles of tensegrity, we can discover a myofascial basis for acupuncture.

James Spears
Integrative Healing Society
email us here
Visit us on social media:

Acupuncture Anatomy and Fasciae

Source: EIN Presswire

Visiopharm and Ultivue form co-marketing partnership, raising the bar for immunoprofiling insights

HOERSHOLM, DENMARK, March 31, 2021 / — Visiopharm, a leader in AI-based digital pathology, and Ultivue, a leader in multiplexing for tissue biomarker analysis, today announced a new co-marketing partnership to promote a workflow with Ultivue´s UltiMapper I/O Immuno8 panel and subsequent image analysis. The workflow will standardize tissue biomarkers investigation of cellular immunophenotypes.

Visiopharm and Ultivue will deliver advanced tissue biomarker staining and analysis research solutions for immuno-oncology programs. The partnership leverages the companies' capabilities and experience in multiplex immuno-profiling to enable its biopharma customers to carry out advanced analysis of the tumor microenvironment. The technologies from both companies are ideally suited to elevate biomarker discovery and analysis within the tumor microenvironment. For biomarker programs, the solution will provide actionable insights to advance tissue biomarker strategies.

Mark Rees, Ph.D., VP of corporate development, Ultivue, said: "Ultivue have the best-in-class multiplex IF technology platform which together with our rapid custom service can deliver high-quality complex assay solutions to Biopharma and CRO partners in record turnaround times. Visiopharm offers the best image analysis technology for immunoprofiling; this exciting new partnership strengthens the workflow and analytics for advanced analysis of the tumor microenvironment, which ensures that we can deliver the essential data that is needed to expedite decision-making in biomarker programs."

Adrian Arechiga, chief marketing officer, Visiopharm, said: "Success in immunotherapy is driving the need for prognostic and predictive assays to inform patient selection and stratification. This requirement can be met by a combination of multiplexed staining, image analysis and artificial intelligence. This co-marketing partnership is underpinned by a joint vision of providing biopharma with exceptional tools for immunoprofiling through spatial analysis of tumor-immune cell interactions. Ultivue's multiplexing kits and Visiopharm's AI-based tissue mining tools are ideally suited to provide high-quality and in-depth insights that can move biomarker programs forward, ultimately resulting in the next generation of assays that may inform patient care."

To learn more about this collaboration, products and events, visit

About Visiopharm

Visiopharm® is a world leader in AI-driven digital pathology solutions. Visiopharm's pioneering image analysis tools support thousands of scientists, pathologists, and image analysis experts in both academic institutions and the biopharmaceutical industry.

AI-based image analysis and tissue mining tools support research and drug development research worldwide, while their CE-IVD APPs support diagnostics. With the most advanced and sophisticated artificial intelligence and deep learning, they deliver tissue data mining tools, precision results, and workflows.

Visiopharm was founded in 2001 and is privately owned. The company operates internationally with over 900 licenses and countless users in more than 40 countries. Company headquarters are in Denmark's Medicon Valley, with further offices in Sweden, United Kingdom, Germany, and the United States. Follow Visiopharm on LinkedIn and Twitter. For other news, visit the Visiopharm Newsroom.

About Ultivue

Ultivue provides researchers in translational medicine with multiplex biomarker assays for tissue phenotyping and digital pathology. Its proprietary InSituPlex technology enables advanced exploration and interrogation of tissue samples for precision medicine research. These highly customizable solutions and scientific consultative approach strengthen and accelerate biomarker discovery and drug development programs. Learn more at

+1 617-945-2662

+45 88 20 20 88
email us here

Source: EIN Presswire

Montis Biosciences appoints René Hoet as Chief Scientific Officer

Montis Biosciences logo

Dr. Hoet brings 25 years of antibody research and development leadership to his new position as Montis Biosciences’ CSO

LEUVEN , BELGIUM, March 31, 2021 / — MONTIS BIOSCIENCES, a discovery stage biotech company focused on the development of novel immuno-oncology therapeutics targeting the interactions between perivascular macrophages and the tumor vasculature, appoints René Hoet, Ph.D. as its Chief Scientific Officer. Dr Hoet brings extensive experience in antibody drug discovery and development, through his international career in Biotech and Pharma.

“We are very pleased that René is joining the Montis Biosciences’ team as its Chief Scientific Officer,” said Montis Biosciences’ CEO Karen Zinkewich-Péotti. “René has a proven track record in discovering and developing novel antibody therapeutics. His knowledge and experience will help us accelerate the translation of our novel immune-oncology approach into the clinic.”

René Hoet, a molecular immunologist by training, was most recently CSO at Imcheck Therapeutics (Marseille, France) where he built a successful antibody R&D group focused on first-in-class immune-oncology antibodies targeting butyrophilins and gamma delta T cells and macrophage subsets. This led to the first gamma delta T cell activating-antibody, which entered the clinic in March 2020.

Prior to Imcheck, René Hoet was Vice President Biologics Research at Bayer AG for eight years, where his team was responsible for antibody discovery and optimization across therapeutic areas, moving multiple antibodies into the clinic. Dr. Hoet also previously led the Product Related Research, Scientific Communication & Translational Research teams at Genmab where he was responsible for antibody discovery programs and actively supported Genmab’s clinical programs.

René Hoet is a Professor of Biopharmaceutics at the University of Maastricht, Dept. Pathology, Netherlands, guiding researchers to use antibodies to bridge the gap between academic research and therapeutic application.

“I am delighted to join Montis Biosciences to develop the next generation of immune-oncology drugs for patients,” said Dr. Hoet. “Montis Biosciences has a unique targeting approach towards perivascular macrophages and tumor vasculature based on the work of world-experts and co-founders Prof. Peter Carmeliet and Prof. Massimiliano Mazzone. I am looking forward to working with them, the entire Montis Team and the Board of Directors to develop a pipeline of innovative immune-oncology therapeutics.”

“I am personally very much looking forward to working with René Hoet to develop promising drugs to combat cancer through innovative approaches,” said Prof. Carmeliet. "René's therapeutic antibody experience will have a big impact on the translation of the science into the clinic and addressing the high level of patient need," added Prof. Mazzone.

Montis Biosciences launched last year, with €8,4 million seed financing and a novel approach to immuno-oncology. Montis Biosciences was founded by Droia Ventures, VIB and KU Leuven based on the innovative science discovered by the labs of Peter Carmeliet (VIB-KU Leuven) and Massimiliano Mazzone (VIB-KU Leuven). The founders were joined by investors Polaris Partners, ALSA Ventures and Pfizer Ventures, the venture capital arm of Pfizer.

About Montis Biosciences
Montis Biosciences develops novel immuno-oncology therapeutics targeting the intersection between vascular dysfunction and immune suppression to treat solid tumors. Based on the work of Profs. Peter Carmeliet and Massimiliano Mazzone, Montis Biosciences created a unique target screening and assay platform to discover novel targets modulating interactions between tumor endothelial cells and perivascular macrophages. Montis Biosciences is backed by leading life science investors Droia Ventures, Polaris Partners, ALSA Ventures and Pfizer Ventures. For more information, please see

Ann Van Gysel
Turnstone Communications
+32 9 218 71 97
email us here

Source: EIN Presswire

Доктор Флориан Конголи – почетный гражданин Рио-де-Жанейро

Доктор Флориан Конголи (Dr Florian Kongoli) - Почетный гражданин Рио-де-Жанейро.

Доктор Флориан Конголи (Dr Florian Kongoli) – Почетный гражданин Рио-де-Жанейро.

Доктор Флориан Конголи (Dr. Florian Kongoli) с дипломом о присвоении ему звания почетного гражданина Рио-де-Жанейро в Большом вестибюле дворца Педро Эрнесто городского совета Рио-де-Жанейро на Флорианской площади, Рио-де-Жанейро

Доктор Флориан Конголи (Dr. Florian Kongoli) с дипломом о присвоении ему звания почетного гражданина Рио-де-Жанейро в Большом вестибюле дворца Педро Эрнесто городского совета Рио-де-Жанейро на Флорианской площади, Рио-де-Жанейро

Доктор Флориан Конголи (Dr. Florian Kongoli) появился на Таймс-сквер в Нью-Йорке 7, 10 и 11 августа 2020 года по случаю получения звания почетного гражданина Рио-де-Жанейро。

Доктор Флориан Конголи (Dr. Florian Kongoli) появился на Таймс-сквер в Нью-Йорке 7, 10 и 11 августа 2020 года по случаю получения звания почетного гражданина Рио-де-Жанейро。

Единственный ученый в мире, удостоенный этого звания

«Я думаю, что для нашего города не только удовольствие, но и честь иметь возможность чествовать доктора Флориана Конголи»”

— Атила Нуньес, муниципальный советник Рио-де-Жанейро

MOSCOW, RUSSIA, March 31, 2021 / — Благодаря единогласно принятому специальному законодательному указу муниципальный совет Рио-де-Жанейро, Бразилия, присвоил доктору Флориану Конголи официальное звание почетного гражданина Рио-де-Жанейро. за значительный вклад в науку и технологии в рамках устойчивого развития.

Д-р Флориан Конголи, президент FLOGEN STARS OUTREACH и генеральный директор FLOGEN Technologies Inc., является единственным ученым в мире, удостоенным этого звания.

«Я пользуюсь этой возможностью, чтобы поздравить доктора Флориана Конголи с справедливым и заслуженным признанием», – сказал Хорхе Фелиппе, президент городского совета Рио-де-Жанейро.

«Я думаю, что для нашего города не только удовольствие, но и честь иметь возможность чествовать доктора Флориана Конголи», – объясняет Атила Нуньес, муниципальный советник Рио-де-Жанейро.

«Хочу поздравить вас с получением почетного гражданства», – пишет Ее Превосходительство Дженнифер Мэй, посол Канады в Бразилии. «Мы всегда гордимся тем, что канадцы блистают за границей, демонстрируя канадские ценности на международной арене».

Почетное звание было присвоено 26 ноября 2019 года во время специального 45-минутного пленарного заседания городского совета, полностью посвященного церемонии награждения д-ра Флориана Конголи. Церемония впервые в истории городского совета прошла на английском языке. Д-р Флориан Конголи организовал в Рио-де-Жанейро в ноябре 2018 г. Саммит по устойчивой промышленной переработке / Sustainable Industrial Processing Summit (SIPS 2018) – крупное мероприятие с рекордным участием 7 лауреатов Нобелевской премии.

Подготовленный по этому случаю документальный фильм на русском языке о докторе Флориане Конголи можно посмотреть здесь:, а полное видео церемонии с другими фотографиями и интервью с доктором Флорианом Конголи можно посмотреть здесь:


Д-р Флориан Конголи – президент FLOGEN STAR OUTREACH, генеральный директор FLOGEN Technologies Inc. и президент Организационного комитета Саммита по устойчивым промышленным процессам (SIPS). Он, среди прочего, является избранным членом Европейско-Средиземноморской академии искусств и наук и был удостоен награды CEO-Monthly в Великобритании в 2017 году за экологическую премию 2017 года от журнала CEO-Monthly. (Резюме:

FLOGEN Stars Outreach ( – это некоммерческая компания, преследующая 3 цели: достижение устойчивого развития с помощью науки и технологий, повышение значимости науки и техники в обществе и должное чествование ученых и инженеров, которых они по праву заслуживают.

FLOGEN Technologies ( – это высокотехнологичный научно-исследовательский институт, занимающийся разработкой новых устойчивых технологий и преобразованием существующих технологий в устойчивые технологии.

SIPS – Саммит по устойчивой промышленной переработке ( – это многопрофильная конференция, посвященная промышленной науке и технике, которая ежегодно проводится в нескольких странах по всему миру со средним участием 500 авторов, научных кругов, представителей промышленности. , правительство и предпринимательство, представляющие в среднем 80 стран. Саммит посвящен цели достижения устойчивости с помощью науки и технологий и регулярно принимает многочисленных лауреатов Нобелевской премии.

Бараа Ноуэйхед / Baraa Noueihed
+1 514-807-8542 ext. 220
email us here

Доктор Флориан Конголи – Новая Кариока в небе Рио-де-Жанейро (Документальный фильм на русском языке о докторе Флориане Конголи)

Source: EIN Presswire

Wonder Spray registered on EPA list N for COVID-19 disinfection


The Environmental Protection Agency (EPA) List N identifies the
disinfectants that are effective for Use Against SARS-CoV-2 (COVID-19).

Wonder Spray’s addition to the EPA List N validates its use in the reopening of schools, and other institutions. Wonder Spray is safe and nontoxic. Other disinfectants are not due to harsh chemicals.”

— Dr. John Burd

SAN DIEGO, CA, USA, March 30, 2021 / — Wonder Spray Listed on the EPA List N Disinfectant List for COVID-19

The Environmental Protection Agency (EPA) List N identifies the disinfectants that are effective for Use Against SARS-CoV-2 (COVID-19). Wonder Spray, a natural, non-toxic disinfectant, has now been added to List N.

EPA expects all products on List N to kill the coronavirus SARS-CoV-2 (COVID-19) when used according to the label directions. Wonder Spray uses a stabilized form of Hypochlorous Acid (HOCI) disinfectant, its
purity validated by third-party labs and tested for stability over extended shelf life.

Dr. John Burd, Chief Executive Officer at Wonder Spray, LLC, shares, “Wonder Spray’s addition to the N List is another validation of potency and its effectiveness as a key tool in the reopening of schools, businesses, sports arenas, restaurants, and other institutions. This approval from the EPA is an important step in our mission to fight pathogens that impact global public health. Other disinfectants currently used against SARS-CoV-2 can cause skin, eye, and throat irritation due to frequent use of harsh chemicals when used according to CDC cleaning protocols, and people are searching for alternatives.”

The approval comes as demand for sanitizers and disinfectants continues to increase due to the COVID-19 pandemic. HOCL breaks down into ordinary saltwater in minutes, so no rinsing is needed. There is no hazardous material management problem and no waiting period to use the space after spraying.

HOCI, also known as Hypochlorous Acid, is naturally produced by the human body’s disease-fighting white blood cells. Wonder Spray’s electrochemically engineered pure HOCI products mimic the HOCI produced inside the human body and the process remains the only scalable manufacturing technology that can produce a pure and stable form of this disinfectant that contains no Hypochlorite (Bleach), no alcohol, no ammonia and has no other harmful contaminants, additives, or buffers. The result is a remarkably effective pathogen-killing HOCl that is used in a range of products for the cleansing, sanitizing, and disinfecting of homes, businesses, and public spaces.

About Wonder Spray, LLC
Wonder Spray, llc is a major distributor of HOCI-based disinfectants and sanitizers, including a wide range of industry-specific electrochemically engineered solutions that precisely mimic the HOCl produced inside the human body. The company's products set the gold standard for efficacy and have been proven pure and stable through third party laboratory-tested review. Wonder Spray’s product line includes a wide range of topical first aid and skin products, mask refresh spray, wound cleansing products, sanitizers, and office/public space foggers and disinfectant solutions. For more information, visit

john burd
Wonder Spray, llc.
+1 619-992-2873
email us here

Wonder Spray uses

Source: EIN Presswire

Nathan Blazei Joins Kymanox as Head of Quality

Nathan Blazei Joins Kymanox as Head of Quality

Kymanox logo

Nathan Blazei joins Kymanox as Head of Quality to further enhance quality, regulatory, and compliance services for life science organizations .

We are excited to welcome Nathan Blazei back to the Kymanox team as Head of Quality. Nathan and his team are leading edge experts who deliver Right First Time quality and compliance solutions.”

— Stephen M. Perry, CEO and Founder at Kymanox

DURHAM, NC, USA, March 30, 2021 / — Kymanox, a full-service life sciences solutions provider supporting commercialization of vital medicines and treatments, is proud to announce the addition of Nathan Blazei as Head of Quality. This new role will allow Kymanox to further enhance quality, regulatory, and compliance services for life science organizations seeking to bring new products to market or improve existing products.

“Life science organizations need to stay apprised of the latest compliance trends, and Kymanox has added an experienced industry expert to help our clients do just that,” said Stephen M. Perry, CEO and Founder at Kymanox. “We are excited to welcome Nathan Blazei back to the Kymanox team as Head of Quality. This new strategic role enhances Kymanox’s ability to guide clients as they face challenges commercializing modern medicines, including gene therapies and advanced combination products. Furthermore, this is another indication of our ongoing commitment to address the evolving landscape of drug development and delivery. Nathan and his team are leading edge experts who deliver Right First Time quality and compliance solutions.”

Nathan Blazei has spent nearly two decades in the life science industry with experience in various quality management system tools, regulatory strategy and filings, product and process development, process validation, continuous improvement methods, auditing and gap assessments, risk management, and regulatory inspection preparation, facilitation, and remediation. Nathan has extensive operating experience having worked for Liquidia, Novartis Vaccines & Diagnostics, Grifols and its predecessor Talecris Biotherapeutics, ev3 (now Covidien), and Boston Scientific. Nathan received a Bachelor of Science degree in Chemical Engineering from the University of Notre Dame and a Master of Engineering degree in Bioengineering from the University of California, San Diego. Nathan is a member of the Regulatory Affairs Professionals Society (RAPS). He is a Certified Quality Auditor (CQA) through the American Society for Quality (ASQ) and holds a Regulatory Affairs Certification (RAC-US) through RAPS. He has presented at domestic and international industry events on various topics relevant to the life sciences.

To learn more about how Kymanox can help you with your complex quality and compliance life science challenges, contact us at or visit today.

Dan Kaus, Head of Marketing & Innovation
email us here
Visit us on social media:

Source: EIN Presswire

Crystal Goliday and 'Never Underestimate Knowledge (NUK)' Highlights Women In STEM, Event Sponsored By Amazon

Never Underestimate Knowledge (NUK) presented ‘Women In STEM’, hosted by Crystal Goliday, MS, MBA and sponsored by Amazon

Never Underestimate Knowledge (NUK) is a 501(c)(3) nonprofit dedicated to inner city youth and domestic violence survivors who have dreams by providing educational, financial, and social resources to thrive in life.

Panelists include Crystal M. Lacey, Esq., Dr. Elise Grace, Kristin D. Rogers, DDS, MSD

UNITED STATES, March 30, 2021 / — Phenomenal women share their journey on how they used their education in science, technology, engineering, and math (STEM) to continue into their impactful careers, Wednesday, March 31st, 2021 virtually on Zoom at 7:00pm Eastern Time at an Amazon sponsored event.

“The Fund Finder for Education,” Crystal Goliday, founded a 501(c)(3) nonprofit organization, Never Underestimate Knowledge (NUK), providing educational, financial, and social resources to inner city youth and domestic violence survivors. Goliday is passionate about evening the unequal disbursement of information provided to black and brown communities, compared to other communities, so this event is one way she plans to take her resources to the next level. The panelists for this motivational event include:
• Crystal M. Lacey, Esq., Patent Attorney
• Dr. Elise Grace, Director, Strategic Alliance
• Kristin D. Rogers, DDS, MSD, Dentist

“I started my careers as a Computer Engineer and worked my way up to the Executive level in the corporate world, being the only woman and black woman at the table. I am doing my part to motivate and encourage my community to pursue their dreams.”–Crystal Goliday, Founder and Executive Director

According to the 2021 article, Women Making Gains in STEM Occupations but Still Underrepresented , the United States Census Bureau reports, “Women are nearly half of the U.S. Workforce but only 27% of STEM Workers. Women made gains – from 8% of STEM workers in 1970 to 27% in 2019 – but men still dominate the field. Men made up 52% of all U.S. workers but 73% of all STEM workers.” Crystal Goliday and Never Underestimate Knowledge will continue to do their part to empower and provide resources.

To date, Never Underestimate Knowledge has successfully awarded THE RHM SCHOLARSHIP to five deserving high school and college students in 2020, which is a scholarship in honor of the late Mother of the NUK Founder and Executive Director, Crystal Goliday. The goal is to award a total of 10 scholarships in 2021, which will happen with the help of the community.

To learn more information about Never Underestimate Knowledge (NUK) and to support the efforts by becoming a sponsor for the next scholarship fundraiser or to simply donate, please visit Follow Never Underestimate Knowledge on Instagram and Facebook for the latest updates.

Never Underestimate Knowledge (NUK) is a 501(c)(3) nonprofit dedicated to providing inner-city youth and domestic violence survivors with educational, financial, and social resources to thrive in life and fulfill their goals. NUK supports youth in their academic endeavors and empowers domestic violence survivors to leave abusive relationships and begin a new life and path to success.

Who wants to go to college at no cost? Crystal Goliday is “The Fund Finder For Education'' who equips scholars with skills to attend their dream university debt free, complete college, and thrive after graduation. Crystal utilizes her wealth of knowledge she acquired while earning three degrees free. Additionally, she was extended the opportunity to attend professional conferences and receive housing at no cost. Crystal was recruited by and relocated to various cities via Fortune 500 companies (Lockheed Martin and Accenture), and founded her 501(c)(3) nonprofit, Never Underestimate Knowledge, through which she provides resources to inner-city youth and domestic violence survivors.

Crystal guides clients via her “secret sauce” to equip them as collegiates who focus solely on education without the stressors of finances. She helps them expand their network with individuals and organizations along their journey. She is a hidden gem in her industry because she can identify other resources beyond scholarships and loans to pay for college tuition, housing, etc. Plus, she has a powerful network that elevates her services to the next level.


Sloane Parker
CG Consulting LLC
+1 202-852-0534
email us here
Visit us on social media:

Never Underestimate Knowledge (NUK) Introduction Video and First NUK Scholarship Announcement

Source: EIN Presswire

Not fear, but goals and perception of others’ behavior makes you favour health-protective measures during lockdown

Fear that you are at particular lethal risk might not be quite as strong of motivation to support strict regulations and drastically change your lifestyle.

The effects of self-control and cooperation emerged above and beyond the effects of variables such as personal cost of engaging in health-protective behaviors, perceived risk and anxiety.”

— Charlotte Kukowski

ZURICH, SWITZERLAND, March 30, 2021 / — Fear that you are at particular lethal risk of COVID-19 infection might not be quite as strong of motivation to support strict government regulations and drastically change your lifestyle as your perception whether others are doing enough to fight COVID-19, concludes a new study looking into data from the United Kingdom and Switzerland. The research paper is to be published in the peer-reviewed scientific journal Social Psychological Bulletin.

While earlier research has mostly looked into factors such as fear, perceived risk, age and political views to determine what makes individuals and societies more or less willing to drastically change their lifestyle and support government-imposed strict restrictions, in order to mitigate the spread of the COVID-19 pandemic, psychologists at the University of Zurich Charlotte Kukowski, Katharina Bernecker and Veronika Brandstätter took a different perspective.

Instead, they chose to find out the impact of people’s perception of others’ behaviour when it comes to the public good, as well as people’s own self-control in sticking to behaviour guidelines. By using data from the United Kingdom and Switzerland, they concluded that, indeed, valuing fair contribution to the public good and the ability to practice self-control make people more likely to undertake health-protective behaviour, though the effects for self-control are not entirely consistent across the countries the authors sampled. Further, people who are more concerned with the cooperation of their fellow citizens and expect them to do their own part are more supportive of government regulations, possibly as a means of ensuring that others comply. However, the authors stress that future studies need to test this possible link.

Successfully overcoming conflicting desires and needs, such as taking public transportation, meeting with friends, and participating in large gatherings, for the benefit of society means that people must practice self-control. People will only be willing to control their desires and needs, however, if they value the higher goal, that is, managing the pandemic, even though their own health-protective behavior might not affect them directly. In this sense, self-control in the service of a societal goal is quite different from self-control for a personal goal, such as sticking to a healthy diet or meeting career goals.: While exercising and career achievements are largely private concerns, we all depend on each other’s cooperation when it comes to a societal goal like managing COVID-19 pandemic. Therefore, in the context of the COVID-19 pandemic, higher goal importance and perception of others’ behavior are key factors in practicing health-protective behavior.

“(…) we would like to emphasise that the effects of self-control and cooperation emerged above and beyond the effects of variables such as personal cost of engaging in health-protective behaviors, perceived risk and anxiety, and political orientation. If future work replicates these findings, one might cautiously conclude that, in a time of crisis, people – including decision-makers – are indeed able to “rise above themselves” and lay aside political differences and personal costs for collective goal attainment,” say the researchers.

The authors note that in collective actions, it is essential that one sees others put in the same effort.

In conclusion, the scientists note that, in order to improve public efforts in combating the COVID-19 pandemic, as well as other collective goals, including climate change mitigation, it is essential that we identify the factors contributing to successful self-control and cooperation in the service of higher, society-level goals.


Research article:

Kukowski, C., Bernecker, K., & Brandstätter, V. (2021). Self-Control and Beliefs Surrounding Others’ Cooperation Predict Own Health-Protective Behaviors and Support for COVID-19 Government Regulations: Evidence From Two European Countries. Social Psychological Bulletin, 16(1), 1-28.


Corresponding author:

Charlotte Kukowski, Department of Psychology at University of Zurich, Switzerland


Dimitar Boyadzhiev
PsychOpen GOLD, Leibniz Institute for Psychology
email us here
Visit us on social media:

Source: EIN Presswire